Analyst Tycho Peterson discusses Quest Diagnostics (DGX)’ Minimal Residual Disease (MRD) on an Analyst/Industry conference call to be held on October 30 at 2:30 pm. Webcast Link
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics’ AD-Detect Alzheimer’s tests show accuracy in study
- Quest Diagnostics price target raised to $200 from $190 at Piper Sandler
- Quest Diagnostics price target raised to $205 from $195 at Truist
- Quest Diagnostics price target raised to $207 from $191 at Morgan Stanley
- Quest Diagnostics price target raised to $195 from $190 at Barclays